Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
EWTX Stock Forecast 2026-2027
$34.43
Current Price
$3.69B
Market Cap
Buy 10
Hold 2
Sell 0
Wall St Analyst Ratings
Distance to EWTX Price Targets
+48.1%
To High Target of $51.00
+30.7%
To Median Target of $45.00
-41.9%
To Low Target of $20.00
EWTX Price Momentum
+1.7%
1 Week Change
+18.5%
1 Month Change
+156.0%
1 Year Change
+38.7%
Year-to-Date Change
-1.6%
From 52W High of $35.00
+183.4%
From 52W Low of $12.15
📊 TOP ANALYST CALLS
Did EWTX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Edgewise Therapeutics is one of their latest high-conviction picks.
Latest EWTX Stock Price Targets & Analyst Predictions
Based on our analysis of 13 Wall Street analysts, EWTX has a bullish consensus with a median price target of $45.00 (ranging from $20.00 to $51.00). The overall analyst rating is Strong Buy (8.8/10). Currently trading at $34.43, the median forecast implies a 30.7% upside. This outlook is supported by 10 Buy, 2 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Yasmeen Rahimi at Piper Sandler, projecting a 48.1% upside. Conversely, the most conservative target is provided by Paul Choi at Goldman Sachs, suggesting a 41.9% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
EWTX Analyst Ratings
10
Buy
2
Hold
0
Sell
EWTX Price Target Range
Low
$20.00
Average
$45.00
High
$51.00
Current: $34.43
Latest EWTX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for EWTX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 17, 2026 | JP Morgan | Tessa Romero | Overweight | Maintains | $45.00 |
| Mar 17, 2026 | Wedbush | Laura Chico | Outperform | Reiterates | $32.00 |
| Feb 27, 2026 | Evercore ISI Group | Cory Kasimov | Outperform | Maintains | $45.00 |
| Nov 14, 2025 | JP Morgan | Tessa Romero | Overweight | Maintains | $34.00 |
| Nov 7, 2025 | Wedbush | Laura Chico | Outperform | Maintains | $32.00 |
| Nov 7, 2025 | RBC Capital | Leonid Timashev | Outperform | Maintains | $50.00 |
| Sep 25, 2025 | Goldman Sachs | Paul Choi | Neutral | Initiates | $20.00 |
| Aug 19, 2025 | JP Morgan | Tessa Romero | Overweight | Maintains | $30.00 |
| Aug 8, 2025 | RBC Capital | Leonid Timashev | Outperform | Maintains | $49.00 |
| Jun 30, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Initiates | $42.00 |
| Jun 5, 2025 | RBC Capital | Leonid Timashev | Outperform | Reiterates | $48.00 |
| May 16, 2025 | JP Morgan | Overweight | Maintains | $N/A | |
| May 9, 2025 | RBC Capital | Outperform | Maintains | $N/A | |
| Apr 21, 2025 | Wedbush | Laura Chico | Outperform | Maintains | $43.00 |
| Apr 3, 2025 | Scotiabank | Louise Chen | Sector Perform | Downgrade | $14.00 |
| Apr 3, 2025 | RBC Capital | Leonid Timashev | Outperform | Maintains | $52.00 |
| Apr 2, 2025 | Piper Sandler | Yasmeen Rahimi | Overweight | Maintains | $51.00 |
| Mar 7, 2025 | Scotiabank | Louise Chen | Sector Outperform | Initiates | $50.00 |
| Mar 4, 2025 | RBC Capital | Leonid Timashev | Outperform | Reiterates | $56.00 |
| Jan 22, 2025 | Stifel | James Condulis | Hold | Initiates | $30.00 |
Edgewise Therapeutics, Inc. (EWTX) Competitors
The following stocks are similar to Edgewise Therapeutics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
EWTX
Edgewise Therapeutics
mkt cap
3.69B
Edgewise Therapeutics, Inc. (EWTX) Financial Data
Valuation Metrics
Market Cap
$3.69B
Enterprise Value
$3.03B
P/E Ratio
N/A
PEG Ratio
-14.3x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+14.4%
Current Ratio
19.9x
Debt/Equity
0.8x
ROE
-34.2%
ROA
-23.0%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Edgewise Therapeutics, Inc. (EWTX) Business Model
About Edgewise Therapeutics, Inc.
What They Do
Develops therapies for rare muscle disorders.
Business Model
Edgewise Therapeutics operates in the biopharmaceutical industry, focusing on the discovery and commercialization of therapies for rare muscle disorders. The company generates revenue by developing innovative small molecule drugs that target proteins critical for muscle function, addressing unmet medical needs in conditions like Duchenne muscular dystrophy.
Additional Information
The company's work is part of a niche market with significant potential for growth, as there is a continuous demand for effective treatments for rare diseases. By leveraging specialized research and development, Edgewise Therapeutics aims to create impactful therapeutic options that can greatly enhance patient care.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
146
CEO
Dr. Kevin Koch Ph.D.
Country
United States
IPO Year
2021
Website
edgewisetx.comEdgewise Therapeutics, Inc. (EWTX) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Can Myqorzo Drive Growth for Cytokinetics Amid Competition?
CYTK enters the commercial stage with FDA-approved Myqorzo for oHCM, eyeing strong market share, but faces stiff competition and execution risks.
Apr 17, 2026
By Zacks Equity Research
Analyst Blog
Latest News
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
18 days ago
Quick Summary
Edgewise Therapeutics granted 72,000 inducement stock options to 4 new non-executive employees as part of its 2024 Inducement Equity Incentive Plan on March 31, 2026.
Why It Matters
The granting of stock options indicates confidence in new hires, potentially enhancing company performance and innovation. This can positively influence stock value and investor sentiment.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
The analyst raised the price target by $11 per share, indicating a positive outlook on the company's performance.
Why It Matters
An increased price target signals bullish sentiment, potentially indicating the company's strong performance or growth prospects, which can attract more investor interest and drive stock prices higher.
Source: The Motley Fool
Market Sentiment:
Positive
Quick Summary
Edgewise Therapeutics presented MESA study data showing sevasemten stabilizes function in Becker muscular dystrophy, with pivotal trial results expected in Q4 2026.
Why It Matters
The MESA data suggest potential efficacy for sevasemten in Becker muscular dystrophy, a market with no current treatments, enhancing Edgewise Therapeutics' value ahead of pivotal trial results in 2026.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Edgewise Therapeutics, Inc. (Nasdaq: EWTX) will participate in the 2026 MDA Clinical and Scientific Conference, focusing on advancements in muscle disease treatment.
Why It Matters
Edgewise Therapeutics' involvement in the MDA conference may indicate advancements in muscle disease treatments, potentially impacting their stock performance and investor confidence in the company’s pipeline.
Source: PRNewsWire
Market Sentiment:
Neutral
Edgewise Therapeutics to Present at the Leerink Global Healthcare Conference on March 11, 2026
1 month ago
Quick Summary
Edgewise Therapeutics (Nasdaq: EWTX) will present at the Leerink Global Healthcare Conference on March 11, 2026, at 1:40 p.m.
Why It Matters
Edgewise's presentation at a major healthcare conference may signal upcoming developments, influencing investor sentiment and potential stock performance.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Edgewise Therapeutics (EWTX) will release 12-week data for EDG-7500 in HCM and Phase 1 data for EDG-15400 in H1 2026. Pivotal results for sevasemten in Becker muscular dystrophy expected Q4 2026.
Why It Matters
Upcoming trial results for Edgewise Therapeutics' drugs could significantly impact stock prices, as positive outcomes may lead to increased market confidence and potential revenue growth.
Source: PRNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About EWTX Stock
What is Edgewise Therapeutics, Inc.'s (EWTX) stock forecast for 2026?
Based on our analysis of 13 Wall Street analysts, Edgewise Therapeutics, Inc. (EWTX) has a median price target of $45.00. The highest price target is $51.00 and the lowest is $20.00.
Is EWTX stock a good investment in 2026?
According to current analyst ratings, EWTX has 10 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $34.43. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for EWTX stock?
Wall Street analysts predict EWTX stock could reach $45.00 in the next 12 months. This represents a 30.7% increase from the current price of $34.43. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Edgewise Therapeutics, Inc.'s business model?
Edgewise Therapeutics operates in the biopharmaceutical industry, focusing on the discovery and commercialization of therapies for rare muscle disorders. The company generates revenue by developing innovative small molecule drugs that target proteins critical for muscle function, addressing unmet medical needs in conditions like Duchenne muscular dystrophy.
What is the highest forecasted price for EWTX Edgewise Therapeutics, Inc.?
The highest price target for EWTX is $51.00 from Yasmeen Rahimi at Piper Sandler, which represents a 48.1% increase from the current price of $34.43.
What is the lowest forecasted price for EWTX Edgewise Therapeutics, Inc.?
The lowest price target for EWTX is $20.00 from Paul Choi at Goldman Sachs, which represents a -41.9% decrease from the current price of $34.43.
What is the overall EWTX consensus from analysts for Edgewise Therapeutics, Inc.?
The overall analyst consensus for EWTX is bullish. Out of 13 Wall Street analysts, 10 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $45.00.
How accurate are EWTX stock price projections?
Stock price projections, including those for Edgewise Therapeutics, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 20, 2026 2:49 AM UTC